Learning from nature: the role of albumin in drug delivery

References

• 1 Elsadek B, Kratz FJ. Impact of albumin on drug delivery – new applications on the horizon. J. Control Rel. 157, 4–28 (2012).
  Medline CASGoogle Scholar
• 2 Woodcock J. Two recent scientific advances underscore an encouraging future for precision medicine at FDA. https://blogs.fda.gov/fdavoice/index.php/tag/targeted-therapies/.
  Google Scholar
• 3 Kenanova VE, Olafsen T, Salazar FB et al. Tuning the serum persistence of human serum albumin domain III: diabody fusion proteins. Protein Eng. Des. Sel. 23(10), 789–798 (2010).
  Medline CASGoogle Scholar
• 4 Bern M, Sand KM, Nilsen J et al. The role of albumin receptors in regulation of albumin homeostasis: implications for drug delivery. J. Control Rel. 211, 144–162 (2015).
  Medline CASGoogle Scholar
• 5 Larsen MT, Kuhlmann M, Hvam ML et al. Albumin-based drug delivery: harnessing nature to cure disease. Mol. Cell. Ther. 4(3), doi:10.1186/s40591-016-0048-8 (2016).
  MedlineGoogle Scholar
• 6 Bernardim B, Cal PMSD, Matos MJ et al. Stoichiometric and irreversible cysteine-selective protein modification using carbonylacrylic reagents. Nat. Commun. 7, 13128 (2016).
  Medline CASGoogle Scholar
• 7 Krall N, da Cruz FP, Boutureira O et al. Site-selective protein-modification chemistry for basic biology and drug development. Nat. Chem. 8(2), 103–113 (2016).
  Medline CASGoogle Scholar
• 8 Spicer CD, Davis BG. Selective chemical protein modification. Nat. Commun. 5, 4740 (2014).
  Medline CASGoogle Scholar
• 9 Sleep D. Albumin and its application in drug delivery. Expert Opin. Drug Deliv. 12(5), 793–812 (2015).
  Medline CASGoogle Scholar
• 10 Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J. Control Rel. 132, 171–183 (2008).
  Medline CASGoogle Scholar
• 11 Wunder A, Stehle G, Sinn H et al. Enhanced albumin uptake by rat tumors. Int. J. Oncol. 11, 497–507 (1997).
  Medline CASGoogle Scholar
• 12 Kudarha RR, Sawant KK. Albumin based versatile multifunctional nanocarriers for cancer therapy: fabrication, surface modification, multimodal therapeutics and imaging approaches. Mater. Sci. Eng. C Mater. Biol. Appl. 81, 607–626 (2017).
  Medline CASGoogle Scholar
• 13 Bhushan B, Khanadeev V, Khlebtsov B et al. Impact of albumin based approaches in nanomedicine: imaging, targeting and drug delivery. Adv. Colloid Interface Sci. 246, 13–39 (2017).
  Medline CASGoogle Scholar
• 14 Gou Y, Zhang Z, Li D et al. HSA-based multi-target combination therapy: regulating drugs’ release from HSA and overcoming single drug resistance in a breast cancer model. Drug Deliv. 25(1), 321–329 (2018).
  Medline CASGoogle Scholar
• 15 An FF, Zhang XH. Strategies for preparing albumin-based nanoparticles for multifunctional bioimaging and drug delivery. Theranostics 7(15), 3667–3689 (2017).
  Medline CASGoogle Scholar
• 16 Battogtokh G, Gotov O, Kang JH et al. Triphenylphosphine-docetaxel conjugate-incorporated albumin nanoparticles for cancer treatment. Nanomedicine (Lond.) 13(3), 325–338 (2018).
  Medline CASGoogle Scholar
• 17 Wang C, Zhang C, Li Z et al. Extending half-life of H-ferritin nanoparticle by fusing albumin binding domain for doxorubicin encapsulation. Biomacromolecules 19(3), 773–781 (2018).
  Medline CASGoogle Scholar
• 18 Norouzi P, Amini M, Mottaghitalab F et al. Design and fabrication of dual-targeted delivery system based on gemcitabine conjugated human serum albumin nanoparticles. Chem. Biol. Drug Des. doi:10.1111/cbdd.13044 (2017) (Epub ahead of print).
  MedlineGoogle Scholar
• 19 Nosrati H, Sefidi N, Sharafi A et al. Bovine serum albumin (BSA) coated iron oxide magnetic nanoparticles as biocompatible carriers for curcumin-anticancer drug. Bioorg. Chem. 76, 501–509 (2018).
  Medline CASGoogle Scholar
• 20 Edelman R, Assaraf YG, Levitzky I et al. Hyaluronic acid-serum albumin conjugate-based nanoparticles for targeted cancer therapy. Oncotarget 8(15), 24337–24353 (2017).
  MedlineGoogle Scholar